ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Zymeworks and AstraZeneca in Carcinoma, Hepatocellular

Their studies and programs in Carcinoma, Hepatocellular, as the condition page counts them: each program at the phase its studies here reached, with their next primary completion here. Counts, not rankings.

Zymeworks×AstraZeneca×In Carcinoma, Hepatocellular×

At a glance

Studies each sponsor leads that are filed under Carcinoma, Hepatocellular, with the companies grouped under it. Every number opens the studies it counts.

ZymeworksAstraZeneca
studies in Carcinoma, Hepatocellular125
open to participants now17
phase 3 studies under way05
reach primary completion within a year13
programswith a study of their own here in two years, as the Carcinoma, Hepatocellular page lists them15

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseZymeworksAstraZeneca
Phase 1

Zymeworks: 1 of its 1 programs at phase 1

  1. Anti-GPC3 Antibody-drug Conjugate ZW251phase 1
100%

AstraZeneca: 1 of its 5 programs at phase 1

  1. SC durvalumab + rHuphase 1
20%
Phase 200%

AstraZeneca: 1 of its 5 programs at phase 2

  1. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2
20%
Phase 300%

AstraZeneca: 3 of its 5 programs at phase 3

  1. durvalumabphase 3
  2. tremelimumabphase 3
  3. rilvegostomigphase 3
60%
Approved, new studies00%00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Zymeworks1 readouts · 0 phase 3··········

Zymeworks, Sep ’27: 1 program whose next study reaches primary completion

  1. Anti-GPC3 Antibody-drug Conjugate ZW251phase 1 · Sep 0 · NCT07164313
·
AstraZeneca4 readouts · 0 phase 3

AstraZeneca, Nov ’26: 2 programs whose next study reaches primary completion

  1. durvalumabphase 3 · Nov 30 · NCT07081633
  2. tremelimumabphase 3 · Nov 30 · NCT07081633
······

AstraZeneca, Jun ’27: 1 program whose next study reaches primary completion

  1. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2 · Jun 30 · NCT06795022
·

AstraZeneca, Aug ’27: 1 program whose next study reaches primary completion

  1. SC durvalumab + rHuphase 1 · Aug 30 · NCT07391670
··
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Zymeworks

New programs 0

None

Study stopped 0

None

Primary completion later 0

None

AstraZeneca

New programs 0

None

Study stopped 0

None

Primary completion later 0

None

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Zymeworks 1 of 1 · AstraZeneca 4 of 5 programs (3 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • Within Carcinoma, Hepatocellular: a program counts when one of its company’s studies of the last two years names Carcinoma, Hepatocellular as its condition, as the condition page counts it; its phase and next readout are its studies’ here. Stage, biomarker and line of therapy are not read yet.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.